
Burosumab well tolerated for XLH in infants younger than 1 year
Burosumab treatment for X-linked hypophosphataemia may begin in the first year of life, suggest phase 2 trial findings published in The Lancet Diabetes & Endocrinology.

Burosumab treatment for X-linked hypophosphataemia may begin in the first year of life, suggest phase 2 trial findings published in The Lancet Diabetes & Endocrinology.
Basket trial findings indicate that vosoritide therapy may improve growth in children with short stature related to rare genetic disorders of the Ras–mitogen-active protein kinase pathway.

We are delighted to welcome you to the 12th Insights into MAnaging Growth for Endocrine nurses (IMAGE) November 2026 Meeting, organised by Springer Health+ IME. This event will be dedicated to the loving memory of Professor Martin Savage and will take place on 5–6 November 2026 in the beautiful and historic city of Seville in Spain.
A 5‑year‑old girl is brought to clinic with a 2.5‑year history of intermittent headaches that have gradually increased in both frequency and intensity. How does the endocrinologist manage this patient?

In our latest expert review, Rosario Ferrigno discusses children born small for gestational age are defined as those having birth weight and/or length below –2 standard deviation score for gestational age.
An artificial intelligence-assisted tool can speed up anthropometric calculations for paediatric endocrinologists monitoring growth in children with achondroplasia, research indicates.

We are excited to welcome you to the Insights into MAnaging Growth for Endocrine nurses (IMAGE) June 2025 Meeting, organised by Springer Healthcare IME. This event will take place on 5–6 June 2025 in the vibrant city of Lisbon in Portugal.

Some children with congenital adrenal hyperplasia (CAH) could benefit from treatment with the aromatase inhibitor anastrozole to optimise their growth potential, US researchers suggest.

In our latest expert review, Afiya Andrews outlines the broad phenotypic spectrum of classical and non-classical growth hormone insensitivity disorders in children.
Researchers have identified novel pathogenic variants that may account for approximately 9% of children with Silver–Russell syndrome who have not previously had a molecular diagnosis and aid understanding of the relationships between genotype and phenotype.